Related Experiment Videos
Pharmacokinetic aspects of caffeine in premature infants
M P De Carolis1, C Romagnoli, U Muzii
1Department of Pediatrics, Catholic University of the Sacred Heart, Rome, Italy.
Insights
Caffeine citrate effectively treats apnea in premature infants. A 10 mg/kg intravenous dose achieves therapeutic caffeine levels, with daily maintenance doses proving sufficient for ongoing treatment.
Area of Science:
- Neonatal Pharmacology
- Pediatric Clinical Pharmacology
Background:
- Premature infants often experience idiopathic apnea, a condition requiring pharmacological intervention.
- Caffeine is a widely used medication for managing apnea of prematurity.
- Understanding caffeine's pharmacokinetic profile in neonates is crucial for optimizing treatment.
Purpose of the Study:
- To investigate the pharmacokinetic profile of caffeine citrate in premature infants.
- To assess the transformation of caffeine to theophylline in neonates.
- To evaluate the efficacy of a single intravenous loading dose and daily maintenance therapy for apnea prophylaxis.
Main Methods:
- Studied 15 premature infants, with 5 receiving a single intravenous dose (10 mg/kg) of caffeine citrate at birth and on day 15.
- Monitored plasma and urinary concentrations of caffeine and theophylline in 10 neonates receiving daily caffeine therapy for idiopathic apnea.
- Analyzed the time course of drug concentrations and urinary xanthine excretion.
Main Results:
- Caffeine is transformed into theophylline in neonates shortly after administration.
- Total urinary xanthines significantly decreased 72 hours after the loading dose on day 15 (p < 0.001).
- The intravenous loading dose of 10 mg/kg rapidly achieved therapeutic caffeine blood levels, and daily maintenance doses were effective.
Conclusions:
- A 10 mg/kg intravenous loading dose of caffeine citrate is effective in rapidly achieving therapeutic blood levels in premature infants.
- Daily maintenance dosing of caffeine is sufficient for the ongoing management of idiopathic apnea in neonates.
- Further metabolism of theophylline contributes to the observed decrease in total urinary xanthines during treatment.
Abstract:
The pharmacokinetic profile of caffeine was studied in 15 premature infants. Five infants received a single intravenous dose of 10 mg/kg of caffeine citrate 100% at birth and on the 15th day of life. Ten neonates were studied during daily therapy with caffeine for prophylaxis of idiopathic apnea. The time course of plasma and urinary concentrations of caffeine and theophylline shows that caffeine is transformed to theophylline at birth, while total urinary xanthines decrease significantly (p less than 0.001) 72 h after the loading dose given on the 15th day of life. During the whole period of treatment, the decrease in total urinary xanthines and the constant urinary percentage elimination of theophylline are due to further metabolism of theophylline. We confirm that the intravenous loading dose of 10 mg/kg can rapidly obtain therapeutic blood levels of caffeine. We also confirm that the maintenance therapy can be carried out with a single daily dose.